Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2022 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
December 14, 2022 08:00 ET | Source: Fortress Biotech, Inc.

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...
December 06, 2022 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
November 14, 2022 16:01 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million Cosibelimab BLA submission for metastatic and locally advanced cutaneous squamous cell carcinoma expected...
October 05, 2022 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on...
October 03, 2022 08:00 ET | Source: Fortress Biotech, Inc.

Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”)...
September 08, 2022 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing...
August 11, 2022 16:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell...
August 11, 2022 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
July 22, 2022 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Appoints David Jin as Chief Financial Officer

MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...